Brief: Hansa Biopharma Announces $70 Mln Non-Dilutive Product Finance Transaction With NovaQuest
18/07/2022 20:04
July 18 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA ANNOUNCES $70 MILLION NON-DILUTIVE PRODUCT
FINANCE TRANSACTION WITH NOVAQUEST TO SUPPORT CONTINUED
DEVELOPMENT OF THE COMPANY'S ANTIBODY-CLEAVING ENZYME TECHNOLOGY
PLATFORM
* HANSA BIOPHARMA - WILL ADVANCE GLOBAL PHASE 3 CLINICAL
TRIAL OF
IMLIFIDASE IN ANTI-GBM ANTIBODY DISEASE
Source text for Eikon: ID:nWkrlZx17
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS